Company news

Beijing Wantai Biological Pharmacy Enterprise Co. Ltd. Class A (SSE:603392) news

Beijing Wantai Biological Pharmacy Enterprise Co. Ltd. Class A news releases on 6ix. Latest, Sep 24, 2026: "Beijing Wantai Biological Pharmacy Enterprise Co.…

Beijing Wantai Biological Pharmacy Enterprise Co. Ltd. Class A (SSE:603392) news

Press releases & updates

"Beijing Wantai Biological Pharmacy Enterprise Co., Ltd."Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026

"Beijing Wantai Biological Pharmacy Enterprise Co., Ltd."Notice on Convening the 1st Extraordinary General Meeting in 2026

"Beijing Wantai Biological Pharmacy Enterprise Co., Ltd."Indicative Announcement on Change in Equity Interests of the Actual Controller and Its Persons Acting in Concert Reaching 1% Threshold

"Beijing Wantai Biological Pharmacy Enterprise Co., Ltd."Announcement on Gratuitous Donation of Certain Shares by Actual Controller

"Beijing Wantai Biological Pharmacy Enterprise Co., Ltd."Special Report on the Deposit, Management and Actual Use of Raised Funds for the First Half of 2026

"Beijing Wantai Biological Pharmacy Enterprise Co., Ltd."Announcement on Redemption at Maturity of Cash Management Products Purchased with Certain Idle Raised Funds and Continued Cash Management

"Beijing Wantai Biological Pharmacy Enterprise Co., Ltd."Announcement on the Company's 9-Valent HPV Vaccine Obtaining Marketing Authorization in Thailand

"Beijing Wantai Biological Pharmacy Enterprise Co., Ltd."Announcement on Resolutions of the 18th Meeting of the 6th Board of Directors

"Beijing Wantai Biological Pharmacy Enterprise Co., Ltd."Announcement on Acceptance of the Clinical Trial Application for the Company's Lyophilized Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)

"Beijing Wantai Biological Pharmacy Enterprise Co., Ltd."Announcement on Expected Loss in Semi-annual Performance for 2026

"Beijing Wantai Biological Pharmacy Enterprise Co., Ltd."Announcement on the Resignation of a Director and General Manager and the Chairman's Assumption of the General Manager's Duties

Announcement on Progress in Using Partial Idle Raised Funds for Cash Management

Announcement on Acceptance of the Marketing Authorization Application for the Live Attenuated Varicella Vaccine

Announcement on Redemption at Maturity of Partial Idle Raised Funds Used for Cash Management

Announcement on the Submission of the WHO Prequalification Application for the Company’s Nine-valent HPV Vaccine

Announcement on the Completion of National (Excluding Hong Kong, Macao, and Taiwan) Market Access for the Company’s 9-Valent HPV Vaccine

Announcement on Directors Not Reducing Their Shareholdings and Early Termination of the Shareholding Reduction Plan

Announcement on Chairman Acting as Secretary of the Board of Directors

Announcement on Resolutions of the 2025 Annual General Meeting

Announcement on "Corporate Value and Return Enhancement" Action Plan 2026

Notice on Convening the 2025 Annual General Meeting

Announcement on Approval Notice of Clinical Trial for Recombinant Trivalent Rotavirus Subunit Vaccine (Escherichia coli)

Announcement on Resignation of Secretary of Board of Directors

Announcement on Redemption at Maturity of Some Idle Raised Funds Used for Cash Management and Continuing Cash Management

Announcement on Approval for Clinical Trials of the Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)

Announcement on Plan of Shareholding Reduction by Directors through Call Auction

Announcement on Expected Loss in Performance for 2025

Announcement on the Periodic Qualification (PQ) by WHO of the Bivalent HPV Vaccine

Announcement on Completing Industrial and Commercial Change Registration and Obtaining Renewed Business License for Wholly-owned Subsidiary

Announcement on Resolutions of the 14th Meeting of the 6th Board of Directors

Announcement on Acceptance of Clinical Trial Application for Recombinant Trivalent Rotavirus Subunit Vaccine (Escherichia coli)

Announcement on Completing Industrial and Commercial Change Registration and Obtaining Renewed Business License

Announcement on Wholly-owned Subsidiary’s Inclusion in the National Immunization Program Vaccine Centralized Procurement Project

Announcement on Acceptance of Clinical Trial Application for Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)

Announcement on Implementing Cancellation of Repurchased Shares and Share Changes

Announcement on Postponing Some Investment Projects Financed by Raised Funds

Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025

Announcement on Resolutions of the 12th Meeting of the 6th Board of Supervisors

Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025

Announcement on Resolutions of the 11th Meeting of the 6th Board of Directors

Announcement on Resolutions of the 10th Meeting of the 6th Board of Directors

Announcement on the First Batch Release Certificate Obtained for 9-Valent Human Papillomavirus (HPV) Vaccine (Escherichia Coli)

Announcement on Convening the 2025 Semi-annual Performance Briefing

Announcement on Expected Decrease in Semi-annual Performance for 2025

Announcement on Initiating Phase III Clinical Trial of Freeze-dried Live Attenuated Varicella-Zoster Vaccine (VZV-7D) and Completing Enrollment of the 1st Subject

Announcement on Redemption at Maturity of Some Idle Raised Funds Used for Cash Management

Announcement on Approval of the Application for Marketing Authorization of 9-valent HPV Vaccine

Announcement on Result of Share Reduction by Shareholder through Call Auction

Announcement on Resolution of the 2024 Annual General Meeting

Announcement on HIV Antibody Urine Self-Test Reagent Passing WHO PQ Certification